Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Preoperative Magnetic Resonance Imaging Findings of the Transition Zone Predict Incidental Prostate Cancer in HoLEP.

Created on 02 Sep 2026

Authors

Toshiki Ito, Yusaku Hisamatsu, Shuhei Mizutani, Takashi Kodama, Shinya Watanabe, Hiroyuki Amano, Teruo Inamoto

Published in

Cancer diagnosis & prognosis. Volume 6. Issue 5. Pages 900-908. Epub Sep 01, 2026.

Abstract

To assess the effectiveness of magnetic resonance imaging (MRI) of the transition zone (TZ) for predicting incidental prostate cancer (iPCa) detected after holmium laser enucleation of the prostate by comparing cases with and without iPCa.
We retrospectively evaluated 136 patients who underwent holmium laser enucleation for benign prostatic hyperplasia (BPH) between June 2022 and April 2025. After excluding seven patients with biopsy-confirmed prostate cancer, data from 114 patients were analyzed and divided into two groups: iPCa (n=17) and BPH (n=97). The preoperative and postoperative outcomes were compared. Univariate and multivariate logistic regression analyses were performed to identify independent predictors of iPCa. MRI assessment focused exclusively on the TZ according to version 2.1 of the Prostate Imaging-Reporting and Data System (PI-RADS).
MRI-TZ findings of a PI-RADS score of 3 or more were significantly more prevalent in the iPCa group than in the BPH group (64.7% vs. 16.5%, p<0.0001). Univariate analysis identified both positive MRI-TZ findings, a prostate-specific antigen (PSA) level greater than 6.2 ng/ml and TZ-adjusted PSA level greater than 0.18 ng/ml/ml as significant predictors of iPCa. However, multivariate logistic regression identified only positive MRI-TZ findings as an independent predictor of iPCa (odds ratio=8.96, 95% confidence interval=2.68-29.9; p=0.0004). No significant differences in postoperative urinary outcomes were observed between the two groups.
Preoperative positive MRI-TZ findings may predict iPCa in patients undergoing holmium laser prostate enucleation and potentially guide individualized perioperative risk stratification.

PMID:
42683356
Bibliographic data and abstract were imported from PubMed on 02 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 2
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement